We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.43B
AUM Growth
+$209M
Cap. Flow
+$182M
Cap. Flow %
12.72%
Top 10 Hldgs %
28.58%
Holding
96
New
13
Increased
36
Reduced
31
Closed
4

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$34M
2
COR icon
Cencora
COR
+$18.2M
3
TDOC icon
Teladoc Health
TDOC
+$17.4M
4
ISRG icon
Intuitive Surgical
ISRG
+$16.6M
5
MCK icon
McKesson
MCK
+$16.1M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
2
ABBV icon
AbbVie
ABBV
+$14.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$12.4M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.74M
5
GKOS icon
Glaukos
GKOS
+$7.91M

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Industrials 0.98%
3 Technology 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$54.8M 3.82%
595,000
-5,000
-0.8% -$422K
JNJ icon
2
Johnson & Johnson
JNJ
$618B
$53.4M 3.72%
325,000
+210,000
+183% +$34M
UNH icon
3
UnitedHealth
UNH
$376B
$42M 2.93%
113,000
+8,000
+8% +$2.77M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$15.9B
$41.1M 2.87%
250,000
+30,000
+14% +$4.94M
ABBV icon
5
AbbVie
ABBV
$443B
$39.8M 2.78%
368,000
-132,000
-26% -$14.1M
MDT icon
6
Medtronic
MDT
$109B
$39.6M 2.76%
335,000
+15,000
+5% +$1.76M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$121B
$36.2M 2.52%
168,421
+53,421
+46% +$11.7M
TDOC icon
8
Teladoc Health
TDOC
$1.22B
$34.5M 2.41%
190,000
+75,000
+65% +$17.4M
GH icon
9
Guardant Health
GH
$21.7B
$34.3M 2.39%
225,000
+55,000
+32% +$8.31M
ELV icon
10
Elevance Health
ELV
$81.5B
$34.1M 2.38%
95,000
+15,000
+19% +$4.82M
CVS icon
11
CVS Health
CVS
$133B
$33.9M 2.36%
450,000
+30,000
+7% +$2.19M
ABT icon
12
Abbott
ABT
$183B
$33M 2.3%
275,000
+125,000
+83% +$14.8M
LLY icon
13
Eli Lilly
LLY
$1.02T
$31.8M 2.21%
170,000
-10,000
-6% -$1.96M
HUM icon
14
Humana
HUM
$43.7B
$28.9M 2.02%
69,000
+11,000
+19% +$4.39M
CNC icon
15
Centene
CNC
$30.7B
$26.8M 1.87%
420,000
+135,000
+47% +$8.36M
CI icon
16
Cigna
CI
$73.7B
$26.6M 1.85%
110,000
-30,000
-21% -$6.69M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.39B
$26.1M 1.82%
87,146
-2,854
-3% -$888K
BSX icon
18
Boston Scientific
BSX
$69.5B
$25.9M 1.81%
670,000
+140,000
+26% +$5.3M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$25.7M 1.79%
150,000
+50,000
+50% +$9.9M
ABMD
20
DELISTED
Abiomed Inc
ABMD
$24.9M 1.73%
78,000
+15,000
+24% +$4.8M
AXNX
21
DELISTED
Axonics, Inc. Common Stock
AXNX
$24.6M 1.71%
410,000
-50,000
-11% -$2.72M
NVCR icon
22
NovoCure
NVCR
$1.73B
$23.8M 1.66%
180,000
+60,000
+50% +$9.49M
EXAS
23
DELISTED
Exact Sciences
EXAS
$23.1M 1.61%
175,000
+100,000
+133% +$13.7M
GILD icon
24
Gilead Sciences
GILD
$162B
$22.6M 1.58%
350,000
-35,000
-9% -$2.26M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$21.7M 1.51%
160,000
– –
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Rhenman & Partners Asset Management held 96 positions worth $1.43B, up 17% from $1.23B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $182M of net new capital in Q1 2021, opening 13 new positions and adding to 36 existing holdings. Its largest new stake was Cencora: 167,957 shares worth $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 98% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $27M trimmed.

  • Rhenman & Partners Asset Management's largest Q1 2021 buy was Cencora: 167,957 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Johnson & Johnson in Q1 2021, an estimated $34M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2021 reduction was BioMarin Pharmaceuticals, cutting an estimated $27M.
  • Rhenman & Partners Asset Management fully exited Agios Pharmaceuticals in Q1 2021, selling an estimated $5.63M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $1.43B portfolio in Q1 2021.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 4 in Q1 2021.
  • Rhenman & Partners Asset Management's portfolio value rose 17% quarter-over-quarter to $1.43B.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2021, filed 14 May 2021.